Qtick
Sign in

Baxter International Inc. (BAX) Competitors & Peers

The 5 largest companies in the same industry as Baxter International Inc., by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.

How we identify peers ↗

TickerRelationshipPriceComparables
ISRGPeer$452.80P/E 54.8RSI 57Cap 160.4 B
MDLNPeer$39.64P/E 90.1RSI 69Cap 34.8 B
BDXCompetitor$211.88P/E 41.9RSI 75Cap 57.7 B
ALCPeer$74.94P/E 56.8RSI 66Cap 36.5 B
WSTPeer$399.81P/E 44.9RSI 58Cap 28.2 B

How these relationships were derived

Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.

Confirmed relationships (cited)

Sourced from a public filing or disclosure — each links to its origin.

  • HALOSupplier

    Own 10-K customer-concentration disclosure: Baxter = 3% of revenue.

    Confirmed — SEC filing / public disclosuresec.gov ↗
  • CHRSSupplier

    Own 10-Q customer-concentration disclosure: Baxter = 91% of revenue.

    Confirmed — SEC filing / public disclosuresec.gov ↗
  • RMTISupplier

    Own 10-K customer-concentration disclosure: BaxterHealthcareOrganization = 0% of revenue.

    Confirmed — SEC filing / public disclosuresec.gov ↗

Model-inferred relationships (unverified)

Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.

  • BDXCompetitor

    Baxter competes directly with BD in the medication delivery and infusion systems markets (Baxter Spectrum infusion systems vs. BD Alaris).

    Model-inferred, unverified — treat as a lead, not evidence
  • CGSupplier

    Carlyle acquired Vantive (Baxter Kidney Care) for $3.8B.

    Model-inferred, unverified — treat as a lead, not evidence
  • DVASupplier

    Baxter supplies dialysate solutions, concentrates, and specialized home dialysis machines to DaVita.

    Model-inferred, unverified — treat as a lead, not evidence